Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Contract/Agreement, Product/Service

NIH Awards Imbed Biosciences $800K SBIR Grant to Kill Bacteria in Biofilms


Imbed Biosciences, Inc. (Imbed) announced today that it has been awarded $800,000 in a Commercialization Readiness Pilot (CRP) grant by the National Institute for Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to support late-stage development of a next-generation wound dressing that can kill bacteria hidden inside the biofilms in wounds and accelerate wound healing. The competitive award comes on the heels of the successful completion of animal studies by the company under prior Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH).

Biofilms are colonies of bacteria on a surface that are insensitive to systemic antibiotics and topical antimicrobials. Chronic wounds, burns, surgical wounds, and all surgical implants are prone to development of mature biofilms that can delay healing by several months and lead to septic shock or amputations.

"This new grant will support late-stage development of an advanced version of our FDA-cleared Microlyte® Matrix product, which will contain a unique combination of silver and gallium metal ions," said Ankit Agarwal, co-founder and CEO of the company and Principal Investigator on the grant. "The microscale architecture of Microlyte® Matrix, which intimately conforms to a wound surface, will facilitate the synergistic action of the two metal ions to penetrate biofilms and kill multispecies bacteria hidden inside."

"This novel antibiofilm dressing could significantly improve healing in high-risk surgeries and reduce the use of antibiotics and painful surgical debridement, saving billions of dollars in healthcare costs," said Dr. Michael Schurr, MD, a critical care surgeon at Mission Hospital in Asheville, NC and a co-investigator on the grant.

Other investigators on the grant include Dr. Gaurav Pranami and Dr. Jeff Dalsin at Imbed, and Prof. Jonathan McAnulty of Surgical Sciences and Prof. Charles Czuprynski of Pathobiological Sciences in the School of Veterinary Medicine at University of Wisconsin-Madison.

About Imbed Biosciences, Inc.

Imbed is a privately held biotech company registered with FDA as a medical device manufacturer with an ISO 13485 certified quality management system. The company has a portfolio of products in the market and in development based on its patented Microlyte Matrix technology to combat local pain and infections in complex wounds. The research is funded in part by NIH grant #SB1AR079347. For more information, please visit www.imbedbio.com.


These press releases may also interest you

at 22:03
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

at 22:00
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

at 21:45
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...

at 21:30
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Will all...

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare's novel SHP2 (Src Homology 2 domain containing...



News published on and distributed by: